Scout Investments’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Scout Investments’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-234,844	Closed	-$26.7M	–	226
2022 Q4	$26.7M	Buy	234,844 +123,821	+112%	+$10.3M	0.55%	67
2022 Q3	$6.87M	Sell	111,023 -18	-0%	-$1.26K	0.14%	170
2022 Q2	$8.86M	Hold	111,041	–	–	0.18%	146
2022 Q1	$11.7M	Sell	111,041 -259,602	-70%	-$25.3M	0.19%	133
2021 Q4	$39.9M	Sell	370,643 -844,699	-70%	-$92.1M	0.58%	56
2021 Q3	$133M	Sell	1,215,342 -139,998	-10%	-$14.5M	1.99%	1
2021 Q2	$127M	Buy	1,355,340 +293,643	+28%	+$27M	1.89%	3
2021 Q1	$97.7M	Buy	1,061,697 +96,600	+10%	+$8.15M	1.47%	3
2020 Q4	$70.6M	Buy	965,097 +51,426	+6%	+$3.82M	1.3%	6
2020 Q3	$71M	Sell	913,671 -269,088	-23%	-$18.5M	1.57%	2
2020 Q2	$65.7M	Buy	1,182,759 +606,271	+105%	+$25.9M	1.57%	2
2020 Q1	$17.1M	Buy	+576,488	New	+$19.5M	0.51%	69

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Scout Investments's HZNP Position: Q1 2023 in Review

Scout Investments sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2023, closing a stake of 234,844 shares — an estimated $26.7M sold.

Scout Investments first reported a position in HZNP in Q1 2020 and held it in 12 quarters. The position peaked at $133M in Q3 2021. 553 funds tracked by Wall St. Rank hold HZNP as of Q1 2023.

Scout Investments reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Scout Investments sold 234,844 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2023, an estimated $26.7M.
Scout Investments first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2020 and held it in 12 quarters.
Scout Investments's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $133M in Q3 2021.
553 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2023.

Based on Scout Investments's 13F filing for Q1 2023, filed 11 May 2023.